Glioma can evade immune surveillance and eradication by upregulating PD-L1 expression, thereby utilizing and selecting the PD-1/PD-L1 axis as a shield for maladaptation, which is beneficial for tumor growth [34]. This evidence concerns the gene CD274 and glioma.